Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Statement of Comprehensive Income
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value (EV)
- Enterprise Value to FCFF (EV/FCFF)
- Selected Financial Data since 2005
- Debt to Equity since 2005
- Price to Sales (P/S) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The company's solvency profile exhibits a consistent strengthening of the balance sheet, characterized by a reduction in debt dependency and an exceptionally high capacity for interest servicing throughout the analyzed period.
- Debt Utilization Trends
- A sustained downward trend is observed across all primary debt metrics from March 2022 through March 2026. The debt-to-equity ratio decreased from 0.14 to 0.09, while the debt-to-capital ratio declined from 0.12 to 0.08. Similarly, the debt-to-assets ratio fell from 0.10 to 0.07. These movements indicate a strategic reduction in leverage and an increased reliance on equity relative to total obligations.
- Financial Leverage Stability
- The financial leverage ratio remained remarkably stable, fluctuating within a narrow range between 1.27 and 1.32. This consistency suggests a disciplined approach to capital structure management, ensuring that the relationship between total assets and shareholder equity remained constant despite the decline in specific debt ratios.
- Interest Coverage Analysis
- The interest coverage ratio demonstrated significant volatility, starting at a peak of 163.24 in March 2022 before declining to a period low of 57.85 by March 2024. A subsequent recovery phase is evident, with the ratio ascending to 108.44 by March 2026. While the ratio experienced a notable contraction, the absolute values remained exceptionally high, indicating a robust ability to service interest expenses from operating profits.
Debt Ratios
Coverage Ratios
Debt to Equity
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Finance lease liabilities, current portion | |||||||||||||||||||||||
| Long-term debt | |||||||||||||||||||||||
| Finance lease liabilities, excluding current portion | |||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||
| Stockholders’ equity | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Debt to equity1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The solvency profile of the organization demonstrates a consistent strengthening of the balance sheet over the period from March 31, 2022, to March 31, 2026. A sustained reduction in financial leverage is evident, driven primarily by a substantial increase in shareholder equity against a backdrop of nearly static debt levels.
- Total Debt Stability
- Total debt has remained remarkably stable throughout the analyzed timeframe. Beginning at 2,700,400 thousand US dollars in March 2022 and ending at 2,706,200 thousand US dollars in March 2026, the total debt obligation experienced only marginal incremental growth. This indicates a strategic decision to avoid additional borrowing and maintain a fixed debt ceiling.
- Stockholders' Equity Expansion
- A strong and continuous upward trend is observed in stockholders' equity, which grew from 19,914,700 thousand US dollars to 31,423,600 thousand US dollars. This represents a significant accumulation of capital over the four-year period, suggesting strong internal capital generation and an increase in the net asset value available to shareholders.
- Debt to Equity Ratio Compression
- The debt to equity ratio has declined steadily from 0.14 in the first quarter of 2022 to 0.09 by the first quarter of 2026. The most pronounced compression occurred between December 2022 and June 2024, after which the ratio stabilized at 0.09. This downward trajectory reflects a diminished reliance on external debt to finance assets and a corresponding improvement in the organization's long-term solvency and financial risk profile.
Debt to Capital
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Finance lease liabilities, current portion | |||||||||||||||||||||||
| Long-term debt | |||||||||||||||||||||||
| Finance lease liabilities, excluding current portion | |||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||
| Stockholders’ equity | |||||||||||||||||||||||
| Total capital | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Debt to capital1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The solvency profile demonstrates a consistent strengthening of the financial position from March 2022 through March 2026. A steady decline in the debt-to-capital ratio indicates a shift toward a more equity-heavy capital structure and a reduction in relative financial leverage.
- Total Debt Evolution
- Debt levels remained remarkably stable throughout the analyzed period, exhibiting only marginal increases. From a balance of 2,700.4 million USD in March 2022, total debt grew slightly to 2,706.2 million USD by March 2026, suggesting an absence of significant new borrowing activities.
- Total Capital Growth
- Total capital experienced substantial growth, rising from 22,615.1 million USD in March 2022 to 34,129.8 million USD by March 2026. This expansion represents a significant increase in the overall funding base, which serves as the primary driver for the improving solvency metrics.
- Debt to Capital Ratio Trend
- The debt to capital ratio followed a progressive downward trajectory, starting at 0.12 in March 2022 and reaching a plateau of 0.08 by September 2024, where it remained constant through March 2026. This reduction from 12% to 8% is a direct result of the total capital expanding while debt remained nearly constant, effectively lowering the proportion of debt used to finance the entity's operations.
The observed patterns reflect an improving solvency posture, characterized by a reduced reliance on borrowed funds relative to the total capital available. This trend indicates an enhancement in long-term financial stability and a decrease in financial risk.
Debt to Assets
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Finance lease liabilities, current portion | |||||||||||||||||||||||
| Long-term debt | |||||||||||||||||||||||
| Finance lease liabilities, excluding current portion | |||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Debt to assets1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The solvency profile exhibits a consistent improvement in financial stability, characterized by a significant expansion of the asset base coupled with a nearly static debt level. This dynamic has resulted in a steady decline in the leverage ratio, indicating a reduced reliance on borrowed funds to support corporate assets.
- Total Debt Stability
- Total debt remained virtually unchanged throughout the analyzed period, moving from $2,700.4 million in March 2022 to $2,706.2 million in March 2026. The absence of significant fluctuations suggests a strategy of maintaining existing debt levels without incurring substantial new liabilities.
- Asset Base Expansion
- A strong upward trend is observed in total assets, which increased from $26.35 billion to $40.87 billion. This represents a substantial growth in the company's resource base, reflecting consistent capital accumulation or asset acquisition over the timeframe.
- Debt to Assets Ratio Analysis
- The debt-to-assets ratio demonstrates a clear downward trajectory, decreasing from 0.10 to 0.07. This contraction confirms a strengthening solvency position, as the proportion of assets financed through debt has diminished steadily, thereby reducing the overall financial risk profile.
Financial Leverage
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||
| Stockholders’ equity | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Financial leverage1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The financial position of the organization is characterized by consistent balance sheet expansion coupled with a highly stable leverage profile. Between March 31, 2022, and March 31, 2026, there was a significant increase in both total assets and stockholders' equity, indicating steady growth in the company's resource base and net worth.
- Asset and Equity Growth Trends
- Total assets grew from 26.35 billion USD in March 2022 to 40.87 billion USD by March 2026, representing a substantial increase in the company's scale. This growth was mirrored by stockholders' equity, which rose from 19.91 billion USD to 31.42 billion USD over the same period. The parallel increase in both metrics suggests that the expansion of the asset base was largely supported by equity growth.
- Financial Leverage Analysis
- The financial leverage ratio remained remarkably consistent throughout the analyzed period, fluctuating within a narrow range between 1.27 and 1.32. A slight downward trend was observed from March 2022 (1.32) to December 2023 (1.27), followed by a marginal stabilization and slight increase to 1.30 by March 2026. This stability indicates a disciplined approach to capital structure, where the proportion of debt relative to equity remained nearly constant despite the overall growth of the balance sheet.
- Solvency Implications
- The maintenance of a low and stable leverage ratio suggests a conservative financial strategy. The company has avoided aggressive borrowing to fund its asset growth, thereby mitigating solvency risk and maintaining a strong equity cushion. The close alignment between asset growth and equity growth confirms that the organization is not becoming overly reliant on external debt to finance its operations or expansions.
Interest Coverage
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Net income | |||||||||||||||||||||||
| Add: Income tax expense | |||||||||||||||||||||||
| Add: Interest expense | |||||||||||||||||||||||
| Earnings before interest and tax (EBIT) | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Interest coverage1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Interest Coverage, Competitors2 | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Interest coverage
= (EBITQ1 2026
+ EBITQ4 2025
+ EBITQ3 2025
+ EBITQ2 2025)
÷ (Interest expenseQ1 2026
+ Interest expenseQ4 2025
+ Interest expenseQ3 2025
+ Interest expenseQ2 2025)
= ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The interest coverage analysis reveals a cyclical trend characterized by an initial significant contraction, a subsequent recovery phase, and a period of stabilization. The ratio shifted from a high of 163.24 in the first quarter of 2022 to a low of 57.85 by the first quarter of 2024, before rebounding and settling at 108.44 by the end of the observed period in March 2026.
- Interest Coverage Ratio Trends
- A prolonged downward trend is observed between March 2022 and March 2024, where the coverage ratio declined by approximately 64.5%. This compression suggests a temporary reduction in the margin of safety for meeting interest obligations. However, a reversal occurred in the second quarter of 2024, with the ratio climbing steadily to reach a secondary peak of 134.19 in June 2025. The final quarters show a moderate decline, indicating a normalization of the company's solvency position.
- Earnings Before Interest and Tax (EBIT) Dynamics
- EBIT exhibits considerable volatility throughout the period. Notable peaks occurred in September 2022 (1,525,100 thousand), June 2024 (1,642,900 thousand), and September 2025 (1,782,600 thousand). These surges in operating profit served as primary catalysts for the recovery of the interest coverage ratio. Conversely, periodic troughs, such as in March 2024 (716,800 thousand) and March 2026 (844,100 thousand), contributed to the downward pressure on the solvency metric.
- Interest Expense Behavior
- Interest expenses remained relatively stable, fluctuating between 13.1 million and 18.9 million for the majority of the timeline. A significant anomaly is observed in June 2025, where interest expenses dropped sharply to 3.6 million. This specific decrease, coinciding with strong EBIT, resulted in a temporary spike in the interest coverage ratio. Following this event, expenses returned to a range of 12.2 million to 12.9 million, aligning with the stabilization of the coverage ratio above 100.
Overall, the company maintains a high capacity to service its debt, as the interest coverage ratio remained well above 50 throughout the entire period. The transition from the 2022 peak to the 2024 trough and the subsequent recovery reflects a dynamic interplay between fluctuating operating earnings and controlled interest costs.